Hepcidin in iron overload disorders

Blood

Volumn 105, Issue 10, 2005, Pages 4103-4105

  Papanikolaou, George ^b   Tzilianos, Michalis ^b   Christakis, John I ^b   Bogdanos, Dionisios ^b   Tsimirika, Konstantina ^b   MacFarlane, Julie ^b   Goldberg, Y Paul ^b   Sakellaropoulos, Nikos ^b   Ganz, Tomas ^a   Nemeth, Elizabeta ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERROPORTIN 1; GENE PRODUCT; HEPCIDIN; JUVELIN; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE 1; FEMALE; GENE MUTATION; HEMOCHROMATOSIS; HOMEOSTASIS; HUMAN; INTERNALIZATION; IRON ABSORPTION; IRON OVERLOAD; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; THALASSEMIA;

EID: 19544386871     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4844     Document Type: Article

References (21)

1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806-7810.
2. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11:251-254.
3. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780-8785.
4. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99:4596-4601.
5. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461-2463.
6. Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100:3776-3781.
7. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037-1044.
8. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-1995.
9. Finch C. Regulators of iron balance in humans. Blood. 1994;84:1697-1702.
10. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis. 2004;32:131-138.
11. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
12. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669-673.
13. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
14. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21-22.
15. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2-hemochromatosis. Blood. 2005;105:1803-1806.
16. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
17. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol. 2004;124:123-124.
18. Rivera S, Liu L, Nemeth E, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105:1797-1802.
19. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104:34-39.
20. Cazzola M, Cremonesi L, Papaioannou M, et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol. 2002;119:539-546.
21. Fleming RE, Sly WS. Ferroprotein mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding. J Clin Invest. 2001;108:521-522.